Celia Bañuls1, Susana Rovira-Llopis1, Rosa Falcón2, Silvia Veses2, Nuria Monzó3, Víctor M Víctor4, Milagros Rocha5, Antonio Hernández-Mijares6. 1. Service of Endocrinology, University Hospital Dr. Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avda. Gaspar Aguilar 90, 46017 Valencia, Spain; Institute of Health Research INCLIVA, Av Blasco Ibáñez 17, 46010 Valencia, Spain. 2. Service of Endocrinology, University Hospital Dr. Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avda. Gaspar Aguilar 90, 46017 Valencia, Spain. 3. Service of Endocrinology, University Hospital Dr. Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avda. Gaspar Aguilar 90, 46017 Valencia, Spain; Department of Medicine, Faculty of Medicine, University of Valencia, Av Blasco Ibáñez 13, 46010 Valencia, Spain. 4. Service of Endocrinology, University Hospital Dr. Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avda. Gaspar Aguilar 90, 46017 Valencia, Spain; Institute of Health Research INCLIVA, Av Blasco Ibáñez 17, 46010 Valencia, Spain; CIBER CB06/04/0071 Research Group, CIBER Hepatic and Digestive Diseases, University of Valencia, Av Blasco Ibáñez 13, 46010 Valencia, Spain; Department of Physiology, Faculty of Medicine, University of Valencia, Av Blasco Ibáñez 13, 46010 Valencia, Spain. 5. Service of Endocrinology, University Hospital Dr. Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avda. Gaspar Aguilar 90, 46017 Valencia, Spain; Institute of Health Research INCLIVA, Av Blasco Ibáñez 17, 46010 Valencia, Spain; CIBER CB06/04/0071 Research Group, CIBER Hepatic and Digestive Diseases, University of Valencia, Av Blasco Ibáñez 13, 46010 Valencia, Spain. Electronic address: milagros.rocha@uv.es. 6. Service of Endocrinology, University Hospital Dr. Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Avda. Gaspar Aguilar 90, 46017 Valencia, Spain; Institute of Health Research INCLIVA, Av Blasco Ibáñez 17, 46010 Valencia, Spain; Department of Medicine, Faculty of Medicine, University of Valencia, Av Blasco Ibáñez 13, 46010 Valencia, Spain. Electronic address: hernandez_antmij@gva.es.
Abstract
BACKGROUND & AIMS: Inositols are thought to be mediators of the insulin signalling pathway. We assessed the effects of inositols on glycaemic control in fasting and postprandial states and evaluated lipoprotein profile and LDL particle size in healthy population. METHODS: A 12-week double-blind clinical trial was performed with forty healthy subjects administered either aninositol-enriched beverage (IEB) -containing 2.23 g of inositols in 250 ml- or a sucrose-sweetened beverage (SB) twice a day. Anthropometric measurements, fasting glucose levels, insulin and HOMA-IR index, lipoprotein profile and postprandial glucose concentrations (measured using the continuous glucose monitoring system (CGMS)) were recorded throughout the intervention period. RESULTS: Following the 12-week trial subjects receiving the IEB exhibited a significant decrease in insulin, HOMA-IR and Apo B and an increase in LDL particle size, whereas the SB group showed increases in BMI and fasting glucose concentration. Analysis of postprandial glucose levels at breakfast, lunch and dinner revealed a mean reduction of glucose of ≈14% and a significant reduction in the area under the curve at 24 h after consumption of the IEB. CONCLUSIONS: Our results show that chronic IEB supplementation induces a significant improvement in carbohydrated metabolism parameters in healthy subjects.
RCT Entities:
BACKGROUND & AIMS:Inositols are thought to be mediators of the insulin signalling pathway. We assessed the effects of inositols on glycaemic control in fasting and postprandial states and evaluated lipoprotein profile and LDL particle size in healthy population. METHODS: A 12-week double-blind clinical trial was performed with forty healthy subjects administered either an inositol-enriched beverage (IEB) -containing 2.23 g of inositols in 250 ml- or a sucrose-sweetened beverage (SB) twice a day. Anthropometric measurements, fasting glucose levels, insulin and HOMA-IR index, lipoprotein profile and postprandial glucose concentrations (measured using the continuous glucose monitoring system (CGMS)) were recorded throughout the intervention period. RESULTS: Following the 12-week trial subjects receiving the IEB exhibited a significant decrease in insulin, HOMA-IR and Apo B and an increase in LDL particle size, whereas the SB group showed increases in BMI and fasting glucose concentration. Analysis of postprandial glucose levels at breakfast, lunch and dinner revealed a mean reduction of glucose of ≈14% and a significant reduction in the area under the curve at 24 h after consumption of the IEB. CONCLUSIONS: Our results show that chronic IEB supplementation induces a significant improvement in carbohydrated metabolism parameters in healthy subjects.
Authors: Sepide Talebi; Mohammad Bagherniya; Stephen L Atkin; Gholamreza Askari; Hossein M Orafai; Amirhossein Sahebkar Journal: Lipids Health Dis Date: 2020-04-11 Impact factor: 3.876
Authors: María de la Fuente-Fernández; Daniel González-Hedström; Sara Amor; Antonio Tejera-Muñoz; Nuria Fernández; Luis Monge; Paula Almodóvar; Laura Andrés-Delgado; Luis Santamaría; Marin Prodanov; Antonio Manuel Inarejos-García; Angel Luis García-Villalón; Miriam Granado Journal: Antioxidants (Basel) Date: 2020-04-21